| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change | | --- | --- | --- | --- | --- | | EPS (GAAP) | $0.16 |$0.14 | $0.20 | (20.0$264.6 million | $262.0 million | N/A | N/A | | Net Product Sales – NUPLAZID |$168.5 million | | $157.4 million | 7.0$96.1 million | | N/A | N/A | | Research & Development Expenses | $78.0 million | |$76.2 million | 2.4% | | Selling, General & Administrative Expenses | $133.5 million | |$117.1 million | 14.0% | Acadi ...